Research programme: isophosphoramide mustard analogues - ZIOPHARM Oncology

Drug Profile

Research programme: isophosphoramide mustard analogues - ZIOPHARM Oncology

Alternative Names: ZIO-202; ZIO-203

Latest Information Update: 21 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Southern Research Institute
  • Developer ZIOPHARM Oncology
  • Class Phosphoramide mustards
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 29 Sep 2005 ZIOPHARM merged with EasyWeb to form ZIOPHARM Oncology
  • 11 Jan 2005 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top